Skip to main content
. 2019 Aug 21;5(1):77–84. doi: 10.1016/j.adro.2019.08.003

Figure 1.

Figure 1

(a-f) Overall survival for all cholangiocarcinoma patients (n = 42) treated with stereotactic body radiation therapy (a) and for patients with intrahepatic (n = 26) versus perihilar (n = 16) cholangiocarcinoma, respectively (b). Panels c to f show disease recurrence in patients with cholangiocarcinoma treated with stereotactic body radiation therapy. The image shows cumulative incidence of (c) local in-field, (d) local out-of-field, (e) regional, and (f) distant failure.